Landscape Capital Management L.L.C. Acquires Shares of 107,753 Kenvue Inc. $KVUE

Key Points

• Landscape Capital Management invested approximately $2.58 million in Kenvue Inc., acquiring 107,753 shares during the first quarter.
• Institutional investors hold 97.64% of Kenvue's shares, with several firms increasing their stakes in the company in the recent quarter.
• Kenvue recently reported earnings of $0.29 per share, exceeding expectations, but experienced a 4.0% revenue decline year-over-year.

Landscape Capital Management L.L.C. acquired a new stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 107,753 shares of the company's stock, valued at approximately $2,584,000.

A number of other institutional investors have also recently made changes to their positions in KVUE. The Manufacturers Life Insurance Company lifted its position in shares of Kenvue by 4.5% in the fourth quarter. The Manufacturers Life Insurance Company now owns 2,235,116 shares of the company's stock worth $47,720,000 after buying an additional 96,540 shares in the last quarter. Cypress Advisory Group LLC purchased a new stake in shares of Kenvue during the 4th quarter worth approximately $750,000. Mercer Global Advisors Inc. ADV raised its holdings in shares of Kenvue by 23.9% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 50,329 shares of the company's stock worth $1,075,000 after acquiring an additional 9,714 shares in the last quarter. Wahed Invest LLC boosted its position in shares of Kenvue by 6.5% during the 4th quarter. Wahed Invest LLC now owns 49,525 shares of the company's stock valued at $1,057,000 after acquiring an additional 3,024 shares during the last quarter. Finally, DoubleLine ETF Adviser LP grew its holdings in shares of Kenvue by 2.4% in the fourth quarter. DoubleLine ETF Adviser LP now owns 106,710 shares of the company's stock valued at $2,278,000 after purchasing an additional 2,521 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Kenvue Trading Up 0.9%

NYSE KVUE traded up $0.18 during trading on Monday, hitting $20.72. The stock had a trading volume of 10,307,391 shares, compared to its average volume of 17,119,262. Kenvue Inc. has a one year low of $19.75 and a one year high of $25.17. The stock has a 50 day simple moving average of $21.46 and a 200 day simple moving average of $22.45. The stock has a market capitalization of $39.76 billion, a price-to-earnings ratio of 27.99, a P/E/G ratio of 2.97 and a beta of 0.83. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The firm had revenue of $3.84 billion for the quarter, compared to the consensus estimate of $3.94 billion. During the same period in the prior year, the business posted $0.32 earnings per share. The company's revenue for the quarter was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Sell-side analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th were given a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a dividend yield of 4.0%. This is a positive change from Kenvue's previous quarterly dividend of $0.21. The ex-dividend date was Wednesday, August 13th. Kenvue's dividend payout ratio is 112.16%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Citigroup reduced their price target on shares of Kenvue from $24.50 to $22.00 and set a "neutral" rating on the stock in a research report on Tuesday, July 15th. Bank of America dropped their price objective on shares of Kenvue from $27.00 to $25.00 and set a "buy" rating for the company in a research note on Tuesday, July 15th. Canaccord Genuity Group decreased their target price on shares of Kenvue from $29.00 to $26.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Zacks Research raised shares of Kenvue to a "strong sell" rating in a report on Monday, August 11th. Finally, Royal Bank Of Canada dropped their price target on Kenvue from $24.00 to $22.00 and set a "sector perform" rating for the company in a research report on Friday, August 8th. Five investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $24.38.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.